Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (trading symbol: MGEN) on February 7, 2020. The filing discloses the pricing of a public offering of common stock and warrants and provides an update on the company's liquidity position. Note: The request metadata references "Viridian Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Miragen Therapeutics, Inc.
Key Financial Metrics and Capital Structure
- Offering Size: 15,000,000 shares of common stock and warrants to purchase 7,500,000 shares.
- Offering Price: $1.00 per unit (one share of common stock and one-half warrant).
- Net Proceeds: Approximately $13.8 million after deducting underwriting commissions, discounts, and estimated offering expenses.
- Warrant Terms: Exercise price of $1.10 per share; exercisable immediately; expire on the fifth anniversary of issuance.
- Liquidity Outlook: Management believes cash, cash equivalents, and short-term investments (as of December 31, 2019), combined with the Offering proceeds and sales under existing purchase agreements, are sufficient to fund operations into the third quarter of 2021.
Material Changes and Events
On February 7, 2020, Miragen entered into an underwriting agreement with Oppenheimer & Co. Inc. as the sole underwriter. The company announced the pricing of the offering, which was previously announced. The offering is expected to close on or about February 11, 2020, subject to customary closing conditions. The shares will be listed on The Nasdaq Capital Market, while the warrants will not be listed on any exchange.
Guidance, Outlook, and Risks
Management Commentary: The company expects the net proceeds to extend its operating runway into Q3 2021. The filing includes forward-looking statements regarding the sufficiency of cash resources and anticipated development milestones.
Risks and Contingencies: The filing references risk factors detailed in the Company's Form 10-Q for the quarter ended September 30, 2019. Key uncertainties include market conditions, the completion of the public offering on anticipated terms, and uncertainties inherent in future clinical trials. The company disclaims any obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the closing of the offering on or about February 11, 2020, and the actual net proceeds received.
- Review the Form 10-Q for the quarter ended September 30, 2019, for detailed risk factors regarding clinical trials and market conditions.
- Monitor the exercise of warrants and any subsequent sales under the Common Stock Purchase Agreement with Aspire Capital Fund, LLC and the Common Stock Sales Agreement with Cowen and Company, LLC.
- Confirm the listing of common stock on The Nasdaq Capital Market post-closing.